The FDA Panel Backed 6 of 7 Peptides and Rejected DSIP. What It Means.
The FDA's own scientists said no to all seven peptides. Its advisory panel said yes to six of them anyway. Across July 23 and 24, 2026 the Pharmacy Compounding Advisory Committee (PCAC) voted to recommend adding BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon to the 503A bulk drug substances list, the list that separates a legal, supervised compounding route from the gray market. On day one, BPC-157, KPV and TB-500 each passed 8 to 6 with 1 abstention and MOTS-c passed 7 to 5 with 2 abstentions. On day two, Semax passed 8 to 5 and Epitalon 7 to 4, each with 1 abstention. Only Emideltide, the nominated name for DSIP, was voted down, 6 to 7 with 1 abstention. Here is the part most coverage rushes past: PCAC is advisory. Its vote is a recommendation to the FDA, not a rule. The FDA makes the final, binding decision through separate rulemaking, it is not required to agree, and as of now it has not acted. So none of these peptides is legally compoundable today, none is an FDA-approved drug, and the DSIP rejection is not a ban either. Anyone telling you BPC-157 is now legal to buy is wrong.
Summarize this article with
What did the FDA advisory panel vote on July 23?
PCAC reviewed seven peptides across July 23 and 24 for the 503A bulks list.1 It recommended six of them for addition, each tied to a specific nominated use, and declined only one. The tallies were close throughout, and the committee was, in the reporting of one attendee, nearly evenly divided.2
| Peptide | Reviewed | Nominated use | PCAC recommendation |
|---|---|---|---|
| Semax | July 24 | cerebral ischemia, migraine and trigeminal neuralgia | Panel recommended addition to the 503A list (8 to 5, with 1 abstention) |
| BPC-157 | July 23 | ulcerative colitis | Panel recommended addition to the 503A list (8 to 6, with 1 abstention) |
| TB-500 | July 23 | wound healing | Panel recommended addition to the 503A list (8 to 6, with 1 abstention) |
| KPV | July 23 | wound healing and inflammatory conditions | Panel recommended addition to the 503A list (8 to 6, with 1 abstention) |
| MOTS-c | July 23 | weight loss | Panel recommended addition to the 503A list (7 to 5, with 2 abstentions) |
| Epitalon | July 24 | insomnia | Panel recommended addition to the 503A list (7 to 4, with 1 abstention) |
| DSIP (Delta Sleep-Inducing Peptide) | July 24 | insomnia, narcotic dependence and opioid withdrawal | Panel voted AGAINST addition to the 503A list (6 to 7, with 1 abstention) |
Source: peptide records in our data file, cross-checked against the FDA advisory-committee page and RAPS. A recommendation is advisory; the FDA makes the binding decision.
The three day-two compounds were taken up on July 24 and split. Semax was recommended 8 to 5 with 1 abstention, for cerebral ischemia, migraine and trigeminal neuralgia. Epitalon was recommended 7 to 4 with 1 abstention, for insomnia. Emideltide, the nominated name for DSIP, was voted down 6 to 7 with 1 abstention, making it the only one of the seven the panel declined to recommend.5 That rejection is worth reading carefully: a vote against is advisory in exactly the same way a vote for is, so it is not a ban, and DSIP is in the same place it was before the meeting, which is research-only with no legal compounding route. The FDA peptide vote tracker carries every per-peptide tally.
Does this mean BPC-157 and these peptides are now legal?
No. This is the single most important thing to get right, and the hype coverage keeps blurring it. PCAC is an advisory committee. Its job is to recommend; the FDA decides. The agency usually, but not always, follows its advisory committees, and here it is weighing a recommendation that directly contradicts its own scientific staff.3 Until the FDA formally adds a peptide to the 503A bulks list, there is no legal compounded route for it. It is not FDA-approved, it is not proven to work, and any vial sold today is still a gray-market product.
A recommendation is not a legalization
"An FDA advisory panel recommended adding these peptides to the compounding list, overriding the FDA's own scientists" is true. "These peptides are now legal to buy" is not. The gap between those two sentences is the entire story. Watch for anyone who collapses it.
Why did the panel override the FDA's own scientists?
Before the meeting, FDA reviewers recommended against adding all seven peptides. Their briefing materials cited compounds that are not well-characterized, little or no human evidence of effectiveness for the proposed (mostly injectable) routes, and insufficient human safety data, including unassessed immunogenicity risk. For KPV, TB-500 and MOTS-c specifically, the agency found no human clinical studies at all supporting the nominated uses.1 Several committee members voted yes anyway, arguing the decision belonged with prescribers and pharmacists rather than the agency, part of a broader 2026 political push to loosen peptide access.3 That is why the votes were close, and why the FDA's final call is genuinely uncertain.
Follow the FDA peptide decisions.
Join the list for evidence-graded updates when the FDA acts. No hype, no gray-market vendors, unsubscribe anytime.
No spam. We never sell your email. Editorial policy.
What happens next, and when?
The decision now sits with the FDA. It reviews the recommendation and decides whether to add each peptide to the 503A list. There is no fixed deadline, and the agency can agree, decline, or add a compound with conditions. The committee's recommendation is one input; the FDA's own reviewers, who opposed all seven, are another. That tension is exactly why the outcome is not a foregone conclusion.
Is it safe to buy these peptides now?
Legality and safety are separate questions, and both point the same way here: not yet. Because there is no legal supervised route, every product currently sold is gray-market, and gray-market peptides carry documented quality problems. Independent testing and FDA findings have turned up peptide products that were mislabeled, underdosed, or contained ingredients not on the label.4 The immunogenicity concern the FDA raised is not theoretical hand-waving; it is why injectable peptides need real characterization data. We do not link or recommend research-chemical vendors, and a favorable committee vote does not change that.
What the vote did not change
The evidence did not move on July 23. Six of these seven peptides are Grade D on our scale (animal studies only); Semax is Grade C (foreign clinical data, no Western replication). A committee recommending a legal route does not add a single human trial. If you are weighing one of these, the honest inputs are the same today as they were last week.
What about peptides for weight loss?
MOTS-c was nominated, and recommended, for weight loss, and it is one of the most-searched peptides for that goal. But its human weight-loss evidence is association-only (Grade D), and even a legal compounding route would not change that. If weight loss is your actual goal, the evidence-backed path is an approved GLP-1 medication, which has the human trial data MOTS-c lacks. For how the licensed telehealth options and compounded-GLP-1 costs compare, our sister site glp1picks.com covers that specific decision in depth. Researching peptides for weight loss and compounded GLP-1 cost are two different questions, and they have two different right answers.
Sources
- FDA: Pharmacy Compounding Advisory Committee, July 23 to 24, 2026 meeting (primary)
- RAPS: FDA advisory committee backs controversial peptides (July 23, 2026 vote coverage)
- NPR: Advisers to the FDA vote to ease regulation of popular peptides (July 23, 2026)
- ProPublica: An FDA reversal on peptides could open the market to unsafe drugs
- RAPS: FDA advisory committee backs two more peptides, rejects one (July 24, 2026 day-two vote coverage)
- Federal Register: FDA-2025-N-6895 (April 2026 503A reclassification, background)
About this article
Written by Best Peptide For That Editorial, Best Peptide For That. All seven vote outcomes verified July 30, 2026 against the FDA advisory-committee page and RAPS reporting for both meeting days. Updated from the original July 24 version, which covered day one only because the day-two tallies had not yet been published. We are an independent publisher, not a medical provider, and nothing here is medical or dosing advice. See our editorial policy for how we grade evidence.